Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3: a pilot study

Arthritis Rheum. 1990 Nov;33(11):1723-7. doi: 10.1002/art.1780331117.


We conducted a 6-month open-label trial in which 10 patients with active psoriatic arthritis received 2 micrograms of oral 1,25-dihydroxyvitamin D3 daily. Statistically significant improvement was noted in the tender joint count and physician global impression. Of these 10 patients, 4 had substantial (greater than or equal to 50%) improvement, and 3 had moderate (greater than or equal to 25%) improvement in the tender joint count. Two patients were unable to receive therapeutic doses because of hypercalciuria. High-dose vitamin D may be a useful therapeutic agent for psoriatic arthritis.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Aged
  • Arthritis, Psoriatic / drug therapy*
  • Calcitriol / administration & dosage
  • Calcitriol / adverse effects
  • Calcitriol / therapeutic use*
  • Calcium / urine
  • Drug Evaluation
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pilot Projects


  • Calcitriol
  • Calcium